Newsletter

Pipeline, markets, policy, and science. Once a week.

You’re in. Check your inbox to confirm.

More stories

In depth

Genmab's Antibody Halves Death Risk in Head and Neck Cancer

Petosemtamab plus Keytruda halved the risk of death versus Keytruda alone in first-line PD-L1-positive head and neck cancer, the first positive Phase 3 in that setting in several years, as Genmab races to replace Darzalex royalties.

Read the story

Pipeline

See all